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cells	 needed	 for	 anti-tumour	 immunity.	 However,	much	 pre-clinical	work	 has	 now	
demonstrated	 that	 in	 addition	 to	 direct	 cytotoxic	 effects	 on	 cancer	 cells,	 a	
proportion	of	DNA	damaging	agents	may	actually	promote	immunogenic	cell	death,	





In	 this	 review,	 we	 discuss	 the	 emerging	 data	 of	 how	 DNA	 damaging	 agents	 can	
enhance	 the	 immunogenic	 properties	 of	 malignant	 cells,	 focusing	 especially	 on	
immunogenic	cell	death,	and	the	expansion	of	neo-antigen	repertoires.	We	discuss	
how	best	to	strategically	combine	DNA	damaging	therapeutics	with	immunotherapy,	
and	 the	 challenges	 of	 successfully	 delivering	 these	 combination	 regimens	 to	
patients.	 With	 an	 overwhelming	 number	 of	 chemotherapy/immunotherapy	
combination	trials	in	process,	clear	hypothesis-driven	trials	are	needed	to	refine	the	
choice	of	combinations,	and	determine	the	timing	and	sequencing	of	agents	in	order	
to	 stimulate	 anti-tumour	 immunological	memory	 and	 improve	maintained	 durable	
response	rates,	with	minimal	toxicity.		
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Without	 doubt,	 a	 subset	 of	 cancer	 patients	 have	 experienced	 tremendous	 benefit	
from	 the	 clinical	 implementation	 of	 immune	 checkpoint	 inhibitors	 and	 naturally	
therefore,	 attention	 is	 now	 focusing	 on	 mechanisms	 by	 which	 primary	 and	
secondary	 resistance	 can	 be	 overcome.	 This	 has	 largely	 been	 approached	 though	
therapeutic	 combination	 strategies	 and	 the	 recent	 publication	 of	 Keynote	 021	
(Langer	et	al,	2016),	demonstrates	that	such	combinations	are	safe	and	can	be	more	
effective	than	chemotherapy	alone.	Keynote	021	is	the	first	trial	to	publish	a	benefit	
of	 immune-checkpoint	 inhibition	 with	 a	 PD1	 inhibitor	 in	 combination	 with	
chemotherapy	 over	 chemotherapy	 alone,	 in	 this	 case	 as	 first	 line	 treatment	 for	
patients	 with	 non-small	 cell	 lung	 cancer	 (NSCLC).	 Whether	 this	 represents	 a	
synergistic	 interaction	 between	 chemotherapy	 and	 immune	 checkpoint	 inhibition	
rather	 than	an	additive	effect	has	 yet	 to	be	established,	however,	 there	 is	 a	 great	
deal	 of	 evidence	 in	 support	 of	 combining	 DNA	 damaging	 agents	 with	 immune	
modulating	drugs.	
	
In	 this	 review	 we	 will	 discuss	 the	 pre-clinical	 rationale	 for	 combining	 immune-
checkpoint	 inhibitors	 with	 DNA	 damaging	 agents.	 We	 will	 summarise	 the	 clinical	




The	host	 immune	 system	actively	protects	 itself	 against	 tumour	development,	 and	
evasion	of	cancer	immunosurveillance	through	both	local	immunosuppression	within	
the	 tumour	 microenvironment	 (TME)	 and	 emergence	 of	 an	 immunoevasive	
phenotype	through	 immunoediting	 is	an	emerging	hallmark	of	many	solid	 tumours	
(Schreiber	et	al,	2011;	Joyce	&	Fearon,	2015).		
	




Immunoediting	 involves	 the	 elimination	 of	 immunologically	 foreign	 tumour	 cells	
through	 the	 activity	 of	 the	 innate	 and	 adaptive	 immune	 systems	 (Schreiber	 et	 al,	
2011).	 This	 may	 serve	 to	 eradicate	 the	 tumour	 entirely,	 or	 as	 a	 result	 of	 tumour	
heterogeneity,	selectively	destroy	highly	immunogenic	tumour	cells,	which	over	time	
results	 in	 a	 tumour	 largely	 composed	 of	 poorly	 immunogenic	 and	 immunoevasive	
cells	(Schreiber	et	al,	2011).		
	
An	 effective	 adaptive	 immune	 response	 requires	 that:	 cytotoxic	 T	 cells	 (CD8+)	 are	
sufficiently	 activated,	 that	 tumour	 specific	 T	 cells	 navigate	 to	 the	 tumour;	
extravasate	 from	 the	 vasculature	 and	 cross	 the	 TME,	 before	 recognising	 and	
responding	to	their	target	antigen.	The	mere	presence	of	tumour	specific	cytotoxic	T	
cells	 therefore,	 is	 not	 sufficient	 for	 immune-mediated	 tumour	 cell	 death	 and	
extrinsic	 to	 the	 tumour	 cells	 themselves,	 early	 adoption	of	 an	 immunosuppressive	
TME	 enables	 tumours	 to	 develop	 in	 what	 are	 essentially	 immune-privileged	 sites	












CTLA-4	 is	 a	 T	 cell	 inhibitory	 receptor	 that	 competitively	 antagonises	 the	 co-
stimulatory	interaction	between	CD28	and	B7	ligand.	Expression	of	CTLA-4	on	T	cells	
is	induced	following	T	cell	activation	where	it	functions	to	attenuate	and	eventually	
terminate	 T	 cell	 activation	 (Sharma	 &	 Allison,	 2015).	 Anti-CTLA-4	 monoclonal	
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antibody	 (mAb)	 treatment	 therefore	 results	 in	 persistent	 T	 cell	 activation	 and	
subsequent	 trafficking	of	T	 cells	 to	 sources	of	antigen.	 Its	use	has	been	associated	
with	 an	 increased	 number	 of	 new	 tumour-specific	 CD8+	 T	 cells	 in	 patients	 with	
melanoma,	 suggesting	 that	 it	 broadens	 the	 immune	 response,	 rather	 than	 just	
stimulating	it	(Kvistborg	et	al,	2014).		It	has	also	been	shown	to	deplete	regulatory	T	
(Treg)	cells	 in	the	tumour	microenvironment	(Simpson	et	al,	2013).	Ipilumumab,	an	









activation,	 can	 induce	 PD-L1	 expression	 on	 a	 range	 of	 cell	 types,	 including	 non-
lymphoid	tissue	such	as	epithelial,	endothelial	and	tumour	cells,	(Sharma	&	Allison,	
2015).	PD-L1	expression	in	tumours	is	therefore	driven	by	the	presence	of	activated	
T	 cells	 in	 the	 TME	 and	 upregulation	 of	 PD-L1	 in	 tumours	 is	 an	 effective	means	 of	




the	 lymphovascular	 system	 (central	 immune	 tolerance),	 whereas	 PD-1	 signalling	
plays	 a	 more	 prominent	 role	 during	 later	 stages	 of	 the	 immune	 response	 and	 is	
required	 for	 the	 inhibition	 of	 T	 cell	 signalling	 in	 peripheral	 tissues	 (peripheral	






DNA	 damage	 arises	 either	 due	 to	 cellular	 exposure	 to	 exogenous	 sources	 of	
damaging	 agents	 such	 as	 chemotherapy,	 or	 because	 of	 a	 failure	 to	 repair	
endogenous	DNA	damage	 in	cells	 (Jackson	&	Bartek,	2009).	DNA	damage	 itself	can	
take	many	different	forms	depending	on	the	mechanism	of	action	of	the	agent	used	
(Box	2),	with	DNA	double	strand	breaks	(DSBs)	considered	to	be	the	most	cytotoxic	
to	 cancer	 cells	 (Brown	 et	 al,	 2017).	 DNA	 damaging	 agents	 are	 widely	 used	 as	
standard	of	care	treatment	across	a	range	of	tumour	types.	 Inhibiting	the	repair	of	
endogenous	or	exogenous	DNA	damage	is	also	an	attractive	anticancer	strategy	and	
several	 different	 DNA	 repair	 inhibitors	 are	 in	 clinical	 development	 (Brown	 et	 al,	
2017).	 Whilst	 in	 this	 review	 we	 will	 focus	 on	 the	 immunomodulatory	 effects	 of	
chemotherapy,	as	well	as	the	newer	DNA	repair	inhibitors,	it	must	be	noted	that	the	
immune	 effects	 of	 radiotherapy	 are	 also	 well-reported	 and	 have	 recently	 been	
reviewed	elsewhere	(Weichselbaum	et	al,	2017).		
	
Traditionally,	 chemotherapy	 has	 been	 considered	 immunosuppressive	 and	 several	
chemotherapeutics,	such	as	methotrexate	and	cyclophosphamide,	are	used	to	treat	
autoimmune	 conditions.	 The	 choice	 of	 DNA	 damaging-therapeutic	 agent,	 dose	 of	
compound	 and	 timing	 of	 these	 combinations	 is	 important	 therefore,	 not	 least	
because	 many	 cytotoxic	 chemotherapeutics	 have	 the	 potential	 to	 deplete	 rapidly	
dividing	 immune-cell	 populations.	DNA	damaging	agents	have	now	been	 shown	 to	






alterations	 accumulated	 by	 cancer	 cells	 during	 tumourigenesis.	 They	 have	 been	
demonstrated	 to	 arise	 from	 various	 processes	 that	 alter	 the	 open	 reading	 frame	
(ORF)	sequences	in	the	genome	(Hacohen	et	al,	2013).	Not	only	missense	mutations,	
but	 also	 fusion	 transcripts,	 frameshifts,	 and	 stop	 losses	 can	 also	potentially	 create	





against	 tumour-specific	 immunogenic	 clonal	 neoantigens	 is	 currently	 not	 a	 high	
throughput	strategy	
	
There	 is	 accumulating	 evidence	 to	 suggest	 that	 high	mutational	 load	equates	with	
increased	 antigenicity,	 however,	 as	 directly	 identifying	 HLA-bound	 neoantigens	 on	
tumour	 tissue	 has	 yet	 to	 be	 successful,	 proving	 this	 association	 definitively	 is	







single	 nucleotide	 variants	 (SNVs)	 as	 a	 measure	 of	 mutational	 load,	 however	 the	
quantity	of	small	 insertions	and	deletions	(indels)	resulting	in	frameshift	mutations,	
also	 correlates	 with	 checkpoint	 inhibitor	 response	 in	 melanoma	 patient	 cohorts	
(Turajlic	 et	 al,	 2017)	 demonstrating	 that	 frameshift	 mutations	 are	 also	 likely	 to	
significantly	contribute	to	neoantigen	repertoire.	In	addition,	frameshift	mutations	in	





repair	 deficiency	 status	 compared	 to	 those	 without	 (Le	 et	 al,	 2015).	 On	 average,	
1,782	somatic	mutations	were	 identified	 in	mismatch	repair-deficient	tumours	 (n	=	
9)	 (by	 far	 surpassing	 the	 mutational	 load	 in	 melanoma	 and	 NSCLC),	 whereas,	 on	
average,	 only	 73	 somatic	 mutations	 were	 observed	 in	 mismatch	 repair-proficient	
tumours	 (n	 =	 6)	 (Le	 et	 al,	 2015).	 This	 is	 predicted	 to	 translate	 into	 20x	 more	




of	CD3+	and	CD8+	tumour	 infiltrating	 lymphocytes	(TILs),	as	well	as	 increased	PD-1	
expression	 on	 TILs	 compared	 to	 microsatellite	 stable	 tumours,	 possibly	 due	 to	
increased	 antigenicity	 (Howitt	 et	 al,	 2015).	 Similarly,	 in	 a	 case	 of	 hypermutated	
glioblastoma	(GBM)	associated	with	a	germline	mutation	 in	DNA	POLE,	 clinical	and	
immunological	 response	 to	 immune	checkpoint	 inhibition	with	pembrolizumab	has	
been	demonstrated	(Johanns	et	al,	2016).		
	
As	 well	 as	 studies	 demonstrating	 associations	 between	 mutational	 load	 and	
response	 to	 immune	 checkpoint	 inhibition,	 a	 recent	 study	 has	 demonstrated	 that	
loss	of	mutation-associated	neoantigens	in	tumours	is	associated	with	resistance	to	
immune	 checkpoint	 inhibitor	 treatment	 in	 patients	with	NSCLC	 (Anagnostou	et	 al,	
2016).	 Interestingly	also,	 intra-tumoural	neoantigen	heterogeneity	has	been	shown	
to	 affect	 response	 to	 immune	 checkpoint	 inhibitors,	with	 higher	 response	 rates	 in	
tumours	 predicted	 to	 have	 a	 high	 clonal	 neoantigen	 burden	 (McGranahan	 et	 al,	
2016).	 It	 is	 possible	 that	 in	 inherently	 immunoevasive	 tumours,	 significantly	
increasing	mutational	load	(i.e.	antigenicity)	lowers	the	threshold	of	immunogenicity	
required	to	result	in	responses	to	immune	checkpoint	inhibition	and	pembrolizumab	
has	 recently	 received	accelerated	FDA	approval	 for	 the	 treatment	of	microsatellite	
instability-high	 (MSI-H)	or	mismatch	 repair	deficient	 (dMMR)	 tumours,	 irrespective	
of	tumour	type.		
	
Similarly	 to	 mismatch	 repair	 deficiency,	 defects	 in	 other	 components	 of	 the	 DNA	
damage	response	also	result	in	unique	mutational	signatures	in	tumours	(Alexandrov	
et	 al,	 2013).	 Breast	 tumours	 from	 patients	 with	 germline	 mutations	 in	 BRCA1	 or	
BRCA2	harbor	a	greater	number	of	clonal	mutations	compared	to	BRCA1/2	wildtype	









unique	 immunological	 characteristics	 and	 at	 least	 BRCA1/2	 mutant	 tumours	 have	
been	shown	to	be	associated	with	higher	 levels	of	tumour	 infiltrating	 lymphocytes,	
increased	secretion	of	lymphocyte	attractants	(eg,	C-X-C	motif	ligand	[CXCL]	10)	and	
upregulation	 of	 immune	 suppressive	 ligands	 such	 as	 PD-L1	 (Mulligan	 et	 al,	 2014;	
Strickland	et	al,	2016).		
	
DNA-damaging	 agents	 are	 mutagenic,	 as	 demonstrated	 by	 the	 increased	 risk	 of	
secondary	 cancers	 following	 treatment	 with	 radiotherapy	 or	 chemotherapeutics	
such	 as	 etoposide	 and	 also,	 by	 the	 mutational	 signatures	 associated	 with	 some	
treatments	 (Alexandrov	et	 al,	 2013;	Murugaesu	et	 al,	 2015).	 Inhibition	 of	 PARP	 in	
sensitive	 tumour	 cells,	 for	 example	 those	 carrying	 mutations	 in	 the	 BRCA	 gene,	




mutagenic	 potential	 of	 DNA	 damaging	 agents	 likely	 differs	 across	 classes	 of	 drugs	
and	 it	 cannot	 be	 assumed	 that	 all	 chemotherapy	will	 increase	 neoantigen	 load	 in	
tumours	equally.	Interestingly,	the	heterogenous	increase	in	mutations	that	arise	as	
a	result	of	treatment	with	DNA	damaging	drugs	such	as	anthracyclines	and	platinum-






A	 number	 of	 chemotherapies,	 including	 gemcitabine,	 oxaliplatin	 and	
cyclophosphamide	 have	 been	 shown	 to	 increase	 antigen	 presentation	 by	 up-
regulating	MHC	class	I	expression	on	tumour	cells	(Liu	et	al,	2010).	The	same	agents	
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have	 also	 been	 shown	 to	 promote	 dendritic	 cell	maturation,	 priming	 them	 for	 an	


















































As	 discussed	 further	 below,	 in	 response	 to	 DNA	 damaging	 chemotherapy,	 the	
cellular	DNA	damage	response	(DDR),	coordinates	signalling	pathways	that	result	in	
the	release	of	pro-inflammatory	cytokines	such	as	NF-κB	and	IFN-α	 (Chatzinikolaou	
et	 al,	 2014).	 The	 release	 of	 cytokines	 into	 the	 extracellular	 space	 has	 a	 bystander	
effect	 on	 neighboring	 cells	 that	 results	 in	 an	 immunogenic	 TME	 (Malaquin	 et	 al,	
2015).	Interestingly,	in	mice	harboring	defects	in	the	nucleotide	excision	DNA	repair	
pathway	 (NER),	 DNA	 damage	 leads	 to	 chronic	 auto-inflammatory	 signaling	
(Karakasilioti	 et	 al,	 2013).	 Persistent	 DNA	 damage	 results	 in	 transcriptional	
derepression	 of	 proinflammatory	 cytokines	 such	 as	 TNFα	 and	 IL-6,	 in	 a	 manner	
dependent	on	the	apical	DDR	signaling	kinases	Ataxia	Telangiectasia	Mutated	(ATM)	
and	Ataxia	Telangiectasia	and	Rad3-Related	Protein	(ATR)	(Karakasilioti	et	al,	2013).		
A	 similar	 phenomenon	 has	 also	 been	 demonstrated	 following	 treatment	 with	 the	
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PARP	 inhibitor	 BMN	 673.	 Treatment	 of	 Brca1-/-	mice	 with	 BMN	 673,	 resulted	 in	








molecular	 signature	 of	 DDR	 deficiency),	 DDR	 deficiency	 was	 associated	 with	
increased	production	of	chemokines	CXCL10	and	CCL5,	both	of	which	are	important	
for	PBMC	chemotaxis	(Parkes	et	al,	2017).		All	these	studies	suggest	that	generating	
chronic	 DNA	 damage	 in	 cancer	 cells,	 particularly	 those	 deficient	 in	 DNA	 repair,	
generates	a	pro-inflammatory	environment	and	immunogenic	tumours.	
	
For	many	DNA	damaging	agents,	 it’s	difficult	 to	tease	apart	effects	on	the	 immune	
system	that	occur	indirectly	as	a	result	of	a	DDR-induced	‘stress’	response	vs	those	
occurring	 independently	 of	DNA	damage.	 Some	 chemotherapies	 are	 recognized	 to	
be	directly	immunomodulatory	however,	with	cyclophosphamide	perhaps	being	the	
best	example	in	this	regard.		Low	dose	cyclophosphamide	treatment	results	in	higher	






Treg	 cells	 in	 the	 TME,	 is	 one	 mechanism	 by	 which	 tumours	 evade	
immunosurveillance	 (Motz	 et	 al,	 2014).	 Cyclophosphamide	 treatment	 has	 been	
shown	to	enhance	the	effects	of	anti-tumour	HER-2/neu	(neu)-targeted	vaccines	 in	
neu-N	 mice,	 at	 least	 in	 part	 through	 depleting	 Treg	 levels	 (Ercolini	 et	 al,	 2005).	
Similarly,	in	mouse	models	of	glioblastoma,	low	dose	temozolamide	has	been	shown	
to	 result	 in	depletion	of	 the	Treg	cell	population	 (Banissi	et	al,	2009).	 Inhibition	of	
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the	 MDSC	 population	 by	 chemotherapy	 such	 as	 gemcitabine	 and	 5-FU	 may	 also	








reported	 a	 downregulation	 of	 PD-L1	 expression	 on	 tumour	 cells	 following	
chemotherapy	(Sheng	et	al,	2016)	or	a	redistribution	of	PD-L1	from	the	cell	surface	
to	 nuclear	 membrane	 (Ghebeh	 et	 al,	 2010).	 Common	 to	 all	 these	 studies,	 is	 the	
notion	 that	 PD-L1	 expression	 is	 dynamic	 and	 can	 be	 affected	 by	 DNA	 damaging	
agents.	Multiple	factors	are	 likely	to	 influence	PD-L1	expression	however,	 including	










Following	 DNA	 damage	 in	 cells,	 the	 DNA	 damage	 response	 (DDR)	 engages	 a	
spectrum	of	signaling	pathways	that	result	in	downstream	activation	of	a	number	of	
effector	 processes	 including:	 DNA	 repair,	 cell	 cycle	 checkpoint	 activation	 and	







DDR	 inhibitors	 have	 the	 potential	 to	 increase	 mutational	 burden	 in	 tumours,	
particularly	 in	 cancers	 with	 high	 levels	 of	 endogenous	 DNA	 damage	 or	 in	
combination	 with	 exogenous	 DNA	 damaging	 agents.	 In	 addition,	 combining	 DNA	
damaging	 agents	 with	 DNA	 repair	 inhibitors	 naturally	 results	 in	 greater	 and	more	
persistent	DNA	damage	and	there	is	intense	interest	in	how	this	may	promote	STING	
activation	 and	 expression	 of	 TH1	 cytokines	 (Härtlova	 et	 al,	 2015).	 Several	 trials	
investigating	 DNA	 repair	 inhibition	 in	 combination	 with	 immune	 checkpoint	
inhibition	are	ongoing	(Brown	et	al,	2017)	(Table	2),	however,	we	must	be	mindful	of	
the	fact	that	an	intact	DDR	plays	an	important	role	in	immunity	and	DDR	inhibition	
has	 the	 potential	 to	 attenuate	 rather	 than	 stimulate	 an	 immune	 response	
(Chatzinikolaou	et	al,	2014).		
	
Many	 key	 players	 in	 the	 DDR	 have	 fundamental	 roles	 in	 innate	 and	 adaptive	
immunity	(Ioannidou	et	al,	2016),	for	example:	Dna-pkcs	knockout	mice	have	severe	
combined	 immunodeficiency	 due	 to	 a	 defect	 in	 V(D)J	 recombination	 and	 Ataxia	
Telangiectasia,	 a	 syndrome	 arising	 due	 to	 germline	 mutations	 in	 ATM	 is	
characterized	in	part	by	an	albeit	variable	 immunodeficient	phenotype.	 In	fact,	 it	 is	
widely	 accepted	 that	 mechanisms	 of	 DNA	 repair	 and	 immunity	 have	 evolved	 in	





al,	 2014).	 The	 DDR	 therefore	 provides	 an	 essential	 link	 between	 the	 detection	 of	
nuclear	DNA	damage	and	an	appropriate	 immune	response	(Ioannidou	et	al,	2016;	
Nakad	&	 Schumacher,	 2016).	 Given	 the	 pro-inflammatory	 effects	 of	 DDR	 signaling	
following	DNA	 damage,	 inhibiting	 these	 processes	 has	 the	 potential	 to	 antagonize	









role	 in	DNA	 repair,	 PARP	has	 a	well-established	pro-inflammatory	 role	 and	 in	 pre-
clinical	 models,	 PARP	 inhibitors	 attenuate	 chronic	 inflammatory	 and	 autoimmune	
conditions	 in	 multiple	 organs	 (Rosado	 et	 al,	 2013).	 	 Recently,	 it	 has	 also	 been	
demonstrated	that	mice	deficient	for	Parp1	and	Parp2	have	a	compromised	immune	
response	 due	 to	 defective	 thymocyte	 maturation	 with	 diminished	 numbers	 of	
peripheral	CD4+	and	CD8+	T	 cells	 (Navarro	et	al,	 2017).	 Treatment	of	homologous	
recombination	deficient	tumours	with	PARP	inhibitors,	particularly	those	with	BRCA1	
or	BRCA1	mutations,	generates	significant	levels	of	DNA	damage	however	(Farmer	et	
al,	 2005)	 and	 there	 may	 be	 a	 threshold,	 above	 which	 the	 DNA	 damage-induced	
stress	signals	overwhelm	the	otherwise	anti-inflammatory	effects	of	PARP	inhibition.	
In	 addition,	 it’s	 possible,	 although	 not	 proven	 that	 in	 the	 context	 of	 synthetic	
lethality,	 PARP	 inhibition	 is	 pro-inflammatory	 due	 to	 overwhelming	 tumour	 cell	
death.	In	BRCA1/2	wild	type	cells,	however,	PARP	inhibitors	may	attenuate	immune	
signaling	 and	 it	 will	 be	 particularly	 interesting	 to	 determine	 whether	 toxicity	 of	







As	 detailed	 in	 this	 review,	 it	 is	 clear	 that	 DNA	 damaging	 agents	 are	 not	 equally	
immunogenic	 and	 therefore	 choice	 of	 combination	 therapies	 with	 immune	
checkpoint	inhibitors	needs	to	be	carefully	considered.	The	strategy	may	also	differ	
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depending	 on	 the	 treatment,	 with	 agents	 that	 result	 in	 immunogenic	 cell	 death	
perhaps	requiring	less	or	different	immune	stimulation	to	those	that	don’t.	In	Brca1-
deficient	mouse	models	of	ovarian	cancer	for	example,	inhibition	of	CTLA-4,	but	not	








are	 hoping	 to	 stimulate.	 Tumour	 cell	 death	 results	 in	 the	 release	 of	 neoantigens	
however,	 into	 the	 TME,	 as	 well	 as	 release	 of	 ‘danger	 signals’	 that	 stimulate	
immunological	memory.	Carefully	designed	trials	therefore	need	to	consider	testing	
whether	 maximal	 tumour	 cell	 death	 (at	 the	 MTD)	 should	 be	 compromised	 in	 an	
effort	to	spare	immunoreactive	T	cell	populations.	It’s	possible	that	lower	doses	may	
offer	 greater	 immune	 modulation	 and	 high	 dose	 cyclophosphamide	 for	 example,	
depletes	dendritic	cell	precursors,	whereas	lower	doses	increase	dendritic	cell	pools	
and	 promote	 T	 cell	 priming	 (Sistigu	 et	 al,	 2011).	 With	 respect	 to	 stimulation	 of	
vaccine	 responses,	 low	 dose	 cyclophosphamide	 has	 a	 narrow	 therapeutic	 window	
(Emens	 et	 al,	 2009).	 Similarly,	 low	 dose	 temozolamide	 (TZ)	 but	 not	 high	 dose	 TZ	
results	 in	 depletion	 of	 the	 Treg	 cell	 population	 (Banissi	et	 al,	 2009).	 In	 pre-clinical	
studies	 of	 tumour-specific	 vaccines,	 chemotherapy	 administration	 at	 a	 dose	 just	




For	 DNA	 damaging	 compounds	 that	 are	 clearly	 immunomodulatory	 beyond	 their	
ability	 to	 cause	 ICD,	 there	 is	 some	 suggestion	 that	metronomic	 regimens	will	 lend	
themselves	 towards	 combination	 strategies	with	 immune	 checkpoint	 inhibitors.	 At	
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least	 for	 some	 DNA	 damaging	 agents	 such	 as	 gemcitabine,	 however,	 cell	 death	
appears	 important	 for	 immunogenicity	 (Nowak	 et	 al,	 2003).	 In	 a	 study	 utilising	
animal	 models	 of	 mesothelioma,	 gemcitabine	 lost	 its	 immunogenicity	 on	
chemoresistant	 cell	 lines,	 when	 apoptosis	 did	 not	 occur	 (Nowak	 et	 al,	 2003).	
Assuming	in	this	instance,	that	the	immunophenotype	of	chemoresistant	vs	sensitive	
tumours	are	equal	(which	may	not	necessarily	be	the	case),	cell	death	was	important	
for	 tumour-antigen	 specific	 leucocyte	 proliferation	 (Nowak	 et	 al,	 2003).	 Certainly,	
pre-clinical	 and	 early	 phase	 clinical	 studies	 should	 investigate	 optimal	 immune-





Most,	 if	 not	 all	 anti-cancer	 combination	 therapies	 are	 currently	 administered	




one	 day	 before	 vaccination	 with	 a	 combination	 gp100	 and	 melanoma	 specific	
antigen	vaccine	resulted	in	a	significantly	improved	long	lasting	memory	CD8+	T-cell	
response	 compared	 to	 vaccine	 alone	 (Nisticò	 et	 al,	 2009).	 In	 a	 phase	 II	 trial	 of	
carboplatin	 and	 paclitaxel	 (carbo/taxol)	 +/-	 concurrent	 or	 phased	 ipilimumab	 (ipi),	
only	 phased	 treatment	 (carbo/taxol	 for	 2	 cycles	 followed	 by	 carbo/taxol/ipi	 for	 4	
cycles)	 showed	 an	 improved	 immune-related	 (ir)	 PFS	 benefit	 over	 chemotherapy	
alone	and	a	trend	towards	an	OS	benefit	in	this	arm	in	patients	with	small	cell	lung	




In	 a	 mouse	 model	 of	 mesothelioma,	 concurrent	 administration	 of	 anti-CTLA-4	
blocking	 antibody	 and	 gemcitabine	 was	 superior	 in	 terms	 of	 overall	 survival	
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compared	to	sequential	administration	of	either	anti-CTLA	antibody	or	gemcitabine	
first	 (Lesterhuis	 et	 al,	 2013).	 These	 studies	 suggest	 that	 upfront	 treatment	 with	
chemotherapy,	 followed	 by	 a	 period	 of	 concurrent	 treatment	 with	 chemotherapy	
and	 immune	 checkpoint	 inhibition	 might	 be	 optimal,	 however,	 further	 studies	
testing	proof	of	concept	data	and	incorporating	PD	endpoints	are	required	in	order	
to	 truly	 establish	 the	 optimal	 scheduling	 in	 the	 clinic.	 Testing	 the	 immunological	
effects	of	 chemotherapy	 combinations	 in	murine	 studies	might	not	provide	all	 the	
answers,	 but	 perhaps	 it	 should	 be	 a	 simple	 precursor	 to	 strengthen	 the	 scientific	
rationale	 of	 a	 large	 and	 costly	 clinical	 trial.	 Similarly,	 a	 case	 could	 be	 made	 for	
randomised	 biomarker	 proof-of-concept	 phase	 2	 trials	 to	 guide	 scheduling	 and	




Published	 and	 presented	 data	 from	 clinical	 trials	 combining	 DNA	 damaging	
chemotherapy	and	immune	checkpoint	inhibitors	suggests	that	these	agents	can	be	
safely	 combined.	 Given	 the	 non-overlapping	 toxicity	 of	 DNA	 damaging	
chemotherapy	 and	 immune	 checkpoint	 inhibition	monotherapy,	 combination	 trials	
have	 been	 able	 to	 achieve	 optimal	 doses	 of	 both	 agents.	 Foreseeable	 challenges	
surround	the	practicalities	of	delivering	both	agents	however.	Many	DNA	damaging	
chemotherapy	 regimens	 incorporate	 significant	 doses	 of	 corticosteroids,	 either	 to	
limit	 hypersensitivity	 reactions,	 or	 as	 part	 of	 the	 anti-emetic	 regimen.	 The	
immunosuppressive	effects	of	steroids	have	the	potential	to	attenuate	the	effects	of	
the	 immune	 checkpoint	 inhibitors,	 although	 there	 is	 limited	 and	 inconclusive	
evidence	 to	determine	how	detrimental	 steroid	use	will	be	on	overall	efficacy.	For	
those	 symptoms	 that	 do	 overlap,	 such	 as	 diarrhoea,	 fatigue	 and	 myalgias,	
determining	 the	 likely	 causative	 agent	will	 be	 challenging	 and	will	 have	 significant	
implications	 on	 the	 overall	management.	 In	 particular,	 oncologists	will	 be	 nervous	
about	 reducing	 the	 dose	 intensity	 of	 chemotherapy,	 particularly	 in	 an	 adjuvant	 or	






checkpoint	 inhibitors	 in	 combination	 with	 DNA	 damaging	 chemotherapies	 (Figure	
2a).	 Between	 the	 four	 anti-PD-1/PD-L1	agents	 that	 are	most	 advanced	 in	 terms	of	
clinical	 development,	 it	 would	 appear	 that	 every	 standard	 of	 care	 chemotherapy	
regimen,	 in	 every	 tumour	 type	 is	 being	 tested	 in	 combination	 with	 at	 least	 one	
immune	 checkpoint	 inhibitor	 (Figure	 2a).	 There	 has	 been	 an	 almost	 exponential	
increase	 in	 the	 number	 of	 immunotherapy/chemotherapy	 trials	 being	 conducted	
over	 the	 last	 12-24	months	 and	 only	 time	will	 tell	whether	 in	 being	 so	 hasty,	 the	
scramble	to	registration	will	truly	pay	off.	To	our	knowledge,	of	those	trials	that	are	
published	or	 that	have	preliminary	data	available,	combination	treatment	with	PD-




combination.	 Equally,	 it	 is	 too	 early	 to	 be	 certain	 of	 whether	 long-term	 survival	
benefit	 is	 improved	 using	 combination	 treatments	 upfront.	 With	 regards	 to	
immunotherapy/DDR	 inhibitor	 combination	 studies,	 a	 phase	 I	 trial	 of	 Durvalumab	
(PDL1	inhibitor)	 in	combination	with	olaparib	(PARP	inhibitor)	has	shown	promising	
anti-tumour	 activity,	 with	 the	 combination	 proving	 to	 be	 safe;	 although	
haematological	 toxicity	 was	 observed	 more	 frequently	 compared	 to	 historical	
olaparib	 monotherapy	 studies	 (Lee	 et	 al,	 2017).	 Further	 studies	 to	 evaluate	 the	
clinical	effectiveness,	as	well	as	 translation	work	 to	understand	 the	synergy	of	 this	
combination	will	be	of	great	interest.	
	
Immunotherapy	 biomarkers	 have	 been	 extensively	 reviewed	 previously	 and	 a	
detailed	 discussion	 here	 is	 beyond	 the	 scope	 of	 this	 review	 (Gibney	 et	 al,	 2016).	
Needless	 to	 say	 however,	 utilizing	 PD	 biomarkers	 should	 be	 a	 compulsory	
component	of	early	phase	combination	studies	in	order	to	determine	optimal	doses	
and	 scheduling	 –	 in	 particular	 identifying	 robust	 biomarkers	 of	 ICD	 and	 cytokine	
	 20	
signatures	of	immune	activation.	Equally,	determining	early	biomarkers	of	response	
should	 be	 incorporated	 into	 all	 trials,	 as	 effective	 patient	 selection	 will	 maximize	




Tumour	 immunobiology	 is	 complex	 and	 the	 extensive	 network	 of	 overlapping	
mechanisms	 utilised	 by	 tumours	 to	 evade	 immunosurveillance	 makes	 optimally	
targeting	 this	 process	 a	 considerable	 challenge.	 Combining	 DNA	 damaging	
chemotherapy	with	immune	checkpoint	inhibitors	has	the	potential	to	reverse	many	
of	 these	 immunoevasive	 strategies.	Many	 unanswered	 questions	 remain	 however,	
including	 choosing	 the	 optimal	 agents,	 determining	 effective	 doses	 and	 schedules	






obvious	 in	 many	 ongoing	 clinical	 studies.	 Many	 chemotherapy/immunotherapy	
combinations	 are	 entering	 late	 phase	 clinical	 studies	 following	 only	 small	 safety-
orientated	 phase	 I	 trials,	 with	 limited	 or	 absent	 investigation	 of	 appropriate	 PD	
biomarkers.	As	we	are	discovering,	there	is	a	sliding	scale	of	immunogenicity	within	
tumours	(Blank	et	al,	2016;	Kingwell,	2016).	At	one	end	of	the	scale,	‘inflammatory’	
tumours	may	 need	minimal	 immune	 stimulation,	 requiring	 combination	 strategies	
only	 upon	 resistance	 to	 immune	 checkpoint	 inhibition.	 At	 the	 other	 end	 of	 the	
spectrum,	 an	 ‘immune	 desert’	 designates	 tumours	 that	 are	 likely	 to	 require	
immunological	 priming	 in	 conjunction	 with	 maximal	 immune	 stimulation	 to	 see	
benefit	 (Figure	 2b).	 It	 Is	 essential	 that	 we	 design	 trials	 that	 incorporate	 not	 only	
patient	 selection	 biomarkers,	 but	 also	 pharmacodynamic	 biomarkers	 that	
consolidate	our	understanding	of	the	biology,	confirm	or	refute	our	hypotheses	and	

































Alkylating	agents	 Alkyl	attachment	to	DNA	 Bendamustine	Cyclophosphamide	Melphalan,	Ifosfamide		Anthracyclines	 Intercalate	DNA	 Doxorubicin	Epirubicin	Antimetabolites	 Cytidine	analogue/ribonucleotide	reductase	inhibitor	Thymidylate	synthase	(TS)	inhibitor	Dihydrofolate	reductase	(DFS)	inhibitor	Inhibits	TS,	DFS	and	glycinamide	ribonucleotide	formyltransferase	
















































































































































































































































































































































































































































Ovary gBRCA Olaparib 1/2 Olaparib	+	Durvalumab	+	Tremelimumab 39 Not	yet	recruiting NCT02953457
NSCLC
HNSCC









BGB-A317 Adv	solid	tumors 2nd	line	+ BGB-290	 1 BGB-A317	+	BGB-290 124 recruiting NCT02660034
Olaparib 1/2Durvalumab 338 recruiting




Pembrolizumab Niraparib 1/2 niraparib	+	pembrolizumab
AZD6738	+	Durvalumabrefractory AZD6738 1 114 recruiting NCT02264678 Has	other	arms	involving	AZD	6738	with	other	agents
1st	line	metastatic Carboplatin	+	paclitaxel	or	pemetrexed	+	Veliparib 2 184 Recruiting
NCT02734004
NA
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INDIRECTLY LIFTING IMMUNOSUPPRESSION increasing cross-presentation





b) FUTURE - IMMUNE BIOMARKER DRIVEN
Patient profiling
Tumour profiling





PD-L1 expression in tumour/stroma













add DD agent at progression
a) CURRENT SCENARIO - DD agent + Immune CheckPoint Combinations trials
Durvalumab 
 +DD agent
Nivolumab 
 +DD agent
Pembrolizumab 
 +DD agent
Atezolizumab
 +DD agent
Brain
Neuroblastoma
HNSCC
NSCLC
SCLC
Mesothelioma
Pancreas
Gastric/Oesophageal
Biliary
Colorectal
Endometrial
 Cervix
Ovary
Bladder
Melanoma
 AML
Hodgkin’s
NHL
Sarcoma
Breast
PD-L1
high lymphocytic infiltration
high PD-L1 expression
minimal lymphocytic infiltration
low PD-L1 expression
